CONTEXT: Launch announcement for a patient-centric chronic pancreatitis registry, PACT-CP. The registry will be Us only and aims to assess unmet needs, therapeutic burden and the overall patient experience.
IMPACT: Low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. ““The PACT-CP Registry study will follow patients for up to five years and be an important source of real-world data that will characterize clinical and patient-reported outcomes, providing valuable insights to Aimmune and to the medical community.””
2. “BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage and treat food and metabolic-related diseases, including exocrine pancreatic insufficiency (EPI), today announced the launch of PACT-CP, a Patient-Centric Chronic Pancreatitis Registry study to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP).”
3. “Data will be collected both during regular office visits and through mobile-friendly direct-to-patient surveys with the goal of better understanding:. Chronic pancreatitis is a chronic inflammatory and fibrotic disease of the pancreas with a prevalence of 42 to 73 per 100,000 adults in the United States.1 Up to 48% of patients with chronic pancreatitis develop EPI1, a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion.2 Impaired food digestion in patients with CP and EPI can result in nutrient malabsorption and malnutrition, as well as disturbed regulation of gastrointestinal (GI) motor and secretory functions.3. “Aimmune is committed to further understanding the impact of EPI on the quality of patients’ lives with chronic pancreatitis,” said Andrew Oxtoby, President and Chief Executive Officer for Aimmune Therapeutics.”
4. “By collecting key information about the participants, including demographics, medical history (including all prior and current treatments for EPI), social history and details about their EPI condition, the registry study will generate critical data about the burden of EPI due to CP and provide important insights about current unmet needs in the lives of these patients.”